Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder

REM sleep behavior disorder (RBD) is strongly associated with development of Parkinson's Disease and other α-synuclein-related disorders. Dopamine transporter (DAT) binding deficit predicts conversion to α-synuclein-related disorders in individuals with RBD. In turn, identifying which individua...

Full description

Saved in:
Bibliographic Details
Published in:NPJ Parkinson's Disease 2019-01, Vol.5 (1), p.2-2, Article 2
Main Authors: Chahine, L M, Iranzo, A, Fernández-Arcos, A, Simuni, T, Seedorff, N, Caspell-Garcia, C, Amara, A W, Comella, C, Högl, B, Hamilton, J, Marek, K, Mayer, G, Mollenhauer, B, Postuma, R, Tolosa, E, Trenkwalder, C, Videnovic, A, Oertel, W
Format: Article
Language:English
Subjects:
Behavior disorders
Biomarkers
Dopamine
Neurodegeneration
Parkinson's disease
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:REM sleep behavior disorder (RBD) is strongly associated with development of Parkinson's Disease and other α-synuclein-related disorders. Dopamine transporter (DAT) binding deficit predicts conversion to α-synuclein-related disorders in individuals with RBD. In turn, identifying which individuals with RBD have the highest likelihood of having abnormal DAT binding would be useful. The objective of this analysis was to examine if there are basic clinical predictors of DAT deficit in RBD. Participants referred for inclusion in the RBD cohort of the Parkinson Progression Markers Initiative were included. Assessments at the screening visit including DAT SPECT imaging, physical examination, cognitive function screen, and questionnaire-based non-motor assessment. The group with DAT binding deficit (  = 49) was compared to those without (  = 26). There were no significant differences in demographic or clinical features between the two groups. When recruiting RBD cohorts enriched for high risk of neurodegenerative disorders, our data support the need for objective biomarker assessments.
ISSN:2373-8057
2373-8057
DOI:10.1038/s41531-018-0073-1